ESRD (END STAGE RENAL DISEASE)
Clinical trials for ESRD (END STAGE RENAL DISEASE) explained in plain language.
Never miss a new study
Get alerted when new ESRD (END STAGE RENAL DISEASE) trials appear
Sign up with your email to follow new studies for ESRD (END STAGE RENAL DISEASE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dialysis gadget aims to clean blood better and boost life quality
Disease control Recruiting nowThis study tests a special cartridge (pHA130) added to regular dialysis to remove toxins that standard dialysis misses. One hundred adults with kidney failure on maintenance dialysis will be split into two groups: one gets the new cartridge once a week plus standard dialysis twic…
Matched conditions: ESRD (END STAGE RENAL DISEASE)
Phase: NA • Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Pig kidney trial offers hope to thousands waiting for transplants
Disease control Recruiting nowThis study is testing whether a kidney from a genetically modified pig can safely work in people with end-stage renal disease who cannot get a human kidney. Up to 50 participants will receive the pig kidney and be followed for at least 24 weeks to check survival, kidney function,…
Matched conditions: ESRD (END STAGE RENAL DISEASE)
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Pig kidney transplant trial offers new hope for kidney patients
Disease control Recruiting nowThis study tests a genetically modified pig kidney (called the 10 GE Xenokidney) in 50 adults with end-stage kidney disease who cannot get a human kidney transplant or face a long wait. The goal is to see if the pig kidney works safely and well, improving survival and quality of …
Matched conditions: ESRD (END STAGE RENAL DISEASE)
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for dialysis patients: drug AP301 targets dangerous phosphate levels
Disease control Recruiting nowThis phase 3 trial tests whether AP301, a drug taken with meals, can safely lower high blood phosphate in people on kidney dialysis. About 264 participants will receive either AP301 or a low-dose version for 8 weeks, then all get AP301 for 24 weeks. The goal is to see if AP301 he…
Matched conditions: ESRD (END STAGE RENAL DISEASE)
Phase: PHASE3 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC